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Interleukin-1 beta converting enzyme is necessary
for development of depression-like behavior
following intracerebroventricular administration
of lipopolysaccharide to mice
Marcus A Lawson1,2, Robert H McCusker1,2,3 and Keith W Kelley1,2,3*
Abstract
Background: Interleukin-1 beta converting enzyme (ICE, caspase 1) is a cysteine protease that processes immature
pro-IL-1β into active mature IL-1β. IL-1β is a pro-inflammatory cytokine that mediates many of the physiological
and behavioral responses to inflammation. Genetic deletion of ICE has previously been shown to prevent some
negative physiologic responses to lipopolysaccharide (LPS)-induced inflammation.
Methods: Here we used a preclinical murine model to test the hypothesis that ICE is necessary for development of
depression-like behaviors following intracerebroventricular (ICV) treatment with LPS. Adult male ICE knockout (ICE KO)
and congenic wild-type C57BL/6 J (WT) mice were administered LPS either ICV at 100 ng/mouse or intraperitoneally
(IP) at 830 μg/kg body weight or an equal volume of saline as controls. Mice were monitored up to 48 h after
treatment for both sickness and depression-like behaviors.
Results: LPS given ICV induced a loss of body weight in both WT and ICE KO mice. This sickness response was similar
between WT and ICE KO mice. As expected, LPS administered ICV increased immobility in the forced swim test (FST)
and decreased sucrose preference in WT mice but no change in either of these two depression-like behaviors was
observed in ICE KO mice. Expression of TNF-α and CD11b in brain was lower in ICE-KO mice at 24 h following ICV
administration of LPS compared to WT mice. In contrast, when LPS was given systemically, sickness response,
depression-like behaviors, and expression of these genes were similar between the two strains of mice.
Conclusions: These findings indicate that ICE plays a specific role in depression-like behavior induced by a central
inflammatory stimuli even though it is not required when LPS is administered systemically.
Background
During the past two decades, substantial support has ac-
cumulated for the idea that the co-morbid symptoms as-
sociated with clinical depression and neurodegenerative
diseases share inflammation as a common an important
component of their etiology [1-3]. Moreover, prevalence
rates for neuropsychiatric disorders along with chronic
inflammatory diseases, such as type II diabetes and heart
disease within the general population, are rapidly increa-
sing [4,5]. Similarly, the incidence of neurodegenerative
diseases such as Alzheimer’s and Parkinson’s is rising,
predominately due to increasing life-span [6,7]. As a re-
sult of these challenges, therapies targeted to alleviate
inflammation are now viewed as potential treatments for
clinical depression [8].
Preclinical research using animals to model human de-
pression has provided significant insight into which in-
flammatory mediators may be good therapeutic drug
targets [9-12]. The overall goal is to diminish inflamma-
tion by blocking the production of inflammatory cytokines
such as IL-1β [13,14]. IL-1β plays a prominent role in neu-
rodegenerative processes [9,15] and has recently been
identified for its role in murine models of depression-like
behavior [10,16]. In agreement with these preclinical
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models, evidence from human studies indicates higher
cerebral spinal fluid IL-1β levels in patients suffering from
acute depression [17].
Systemic administration of lipopolysaccharide (LPS)
induces expression and activity of interleukin-1ß (IL-1β)
and IL-1β-converting enzyme (ICE) in myeloid-derived
cells that are resident to many organs, including brain
microglia [18,19]. ICE is the primary enzyme responsible
for cleavage of pro-IL-1β and pro-IL18 to fully processed
mature cytokines, eventually leading to increased secre-
tion of active IL-β and IL-18. ICE activation is linked to
assembly and activation of the inflammasome following
recognition of numerous pathogen- or danger-associated
molecular patterns and toll-like receptor binding [20-22].
ICE activity has been shown to influence food intake dur-
ing inflammation [23,24], presumably through its role in
processing IL-1β. Evidence from experiments utilizing ICE
KO mice demonstrated that these mice have impaired
processing of pro-IL-1ß and reduced secretion of IL-1β
following stimulation with LPS [19]. IL-1β plays a promin-
ent role in brain during inflammation as first evidenced by
experiments that demonstrated IL-1β-induced activation
of hypothalamic-pituitary-adrenal axis and stress respon-
ses [25-27]. Further, ongoing research continues to
highlight the influence of IL-1β in many chronic inflam-
matory diseases and mood disorders. Thus targeting of
ICE represents a possible alternative therapeutic route
to target IL-1β.
We examined the role of ICE in depression-like beha-
viors utilizing murine models of systemic and central in-
flammation following an IP (systemic) or ICV (central)
injection of LPS, respectively. Based on our previously
published results [23,24], we hypothesized that ICE KO
mice would be protected from depression-like behavior
induced by centrally administered LPS but not from
depression-like behaviors induced by systemic LPS. Here
we report that ICE KO mice were protected from central
inflammation-induced depression-like behavior as mea-
sured by two well-accepted behavioral tests [28]. How-
ever, when challenged with systemic LPS, ICE KO mice
displayed depression-like behaviors comparable to WT
mice. This disparate behavioral response corresponds to
decreased brain expression of pro-inflammatory cyto-
kines and markers of glial activation in ICE KO mice fol-
lowing ICV but not IP LPS. Consequently, therapies
designed to inhibit ICE activity may be a viable treat-
ment of comorbid depression associated with inflamma-
tory diseases of the central nervous system.
Methods
Animals
C57BL/6 J (WT) mice were purchased from Jackson La-
boratories (Stock #000664, Bar Harbor, ME, USA). ICE
KO mice on a C57BL background were kindly provided
by Dr. Richard Flavell (Yale University School of Medicine
[29]). These mice are genetically identical to mice now
also available from Jackson Laboratories (Stock #016621).
In these experiments, WT and ICE KO male mice were
individually housed and provided ad libitum access to
Teklad 8640 chow and water in a temperature- (23°C) and
humidity- (45%) controlled room and maintained on a
12:12 hour light:dark cycle (lights off at 10:00). Mice were
acclimated to these conditions for at least 2 weeks prior to
initiation of any procedure. When mice reached at least
10 weeks of age, those mice to be treated ICV were sur-
gically implanted with a guide cannula (Plastics One,
Roanoke, VA, USA) directed toward the lateral ventricle
as previously described [30]. The coordinates for im-
plantation were determined utilizing The Mouse Brain in
Stereotaxic Coordinates [31] and cannulas were placed at
1.5 mm lateral, 0.6 mm posterior, and 1.3 mm dorsal with
respect to bregma. These coordinates placed the guide
cannula 1 mm dorsal to the lateral ventricle. Mice were
allowed to recover from surgery for 10 to 14 days before
being treated. Prior to any treatment, mice were handled
daily to habituate them to being restrained and mani-
pulated. All procedures performed on the mice were in
compliance with the National Institutes of Health guide-
lines and approved by the University of Illinois at Urbana
Champaign Institutional Animal Care and Use Committee.
Treatments
Body weights were measured on the day of treatment
prior to injections and 24 h later to evaluate sickness re-
sponse. Mice were injected using a single internal in-
jector cannula for mice (Plastics One, Roanoke, VA,
USA) which extended 1 mm beyond the tip of the guide
cannula to reach the lateral ventricle. Mice were injected
at the onset of the dark cycle using a 10 μL gas-tight syr-
inge (SGE Incorporated, Austin, TX, USA) to administer
1 μL of endotoxin free phosphate buffered saline (PBS)
or 100 ng LPS (from Escherichia coli O127:B8, Sigma
Aldrich, St Louis, MO, USA) in PBS. The injector can-
nula was left in place for approximately 30 s to allow for
diffusion before dummy cannulas were placed back in
guide cannulas.
Mice treated peripherally were weighed as described
for central LPS studies. Mice were treated IP with either
endotoxin-free injectable saline or LPS (830 μg/kg body
weight) mixed with injectable saline.
Locomotor activity
To evaluate the effects of saline or LPS on exploratory
locomotor activity, mice were tested 24 h after treat-
ment. Mice were placed in clear plexiglass cages identi-
cal to their home cage but devoid of bedding or nesting
material. Clear plexiglass lids were placed on top of test
cages to prevent escape while facilitating video recording
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of mice. Locomotor activity was assessed by virtual div-
ision of the cage into equal quadrants and then tallying
the number of line crossings and rearings each mouse
displayed during the 5-minute test period. Videos were
scored by trained personnel blinded to treatment.
Forced swim test
To determine whether LPS injected ICV or IP induced
differential depression-like behaviors of ICE KO mice
compared to WT mice, we utilized a modified version of
the Porsolt Forced Swim Test [32]. Mice were placed in
a white plastic container (20 cm diameter × 24 cm tall)
that was partially filled with 24 ± 0.5°C water. Test dur-
ation was 5 min and the mice were video-recorded for
analysis. Videos were scored by trained personnel blin-
ded to treatment. Time of immobility was defined as the
time when the mouse’s effort was only that necessary to
remain afloat. The forced swim test was administered
24 h after treatment.
Sucrose preference test
To quantify inflammation-induced anhedonia, which is a
common symptom of major depression, we subjected
mice to the two-bottle sucrose preference test. This test
measures preference for sweetened solution over water.
Approximately 1 week prior to treatment, mice were
trained by simultaneous presentation with a bottle of
water and a bottle of 1% (wt/vol) sucrose solution. Bottles
were weighed prior to being placed on the lid of the
mouse’s home cage and left in place for 24 h periods. Mice
were allowed ad libitum access to the bottles. After 24 h,
the bottles were reweighed to determine the amount of
sucrose solution and water that had been consumed. Pre-
ference was calculated as a percentage of sucrose solution
consumed compared to the total fluid intake (sucrose/
(sucrose + water) * 100). Mice were trained until a stable
baseline preference was established and then treatments
were administered. Following treatment, sucrose prefer-
ence testing was conducted 24 to 48 h following treat-
ment. This time frame corresponded with amelioration of
overt sickness response and presence of depression-like
behavior, as assessed by the FST.
Tissue collection
At either 4 or 24 h post-injection, mice were euthanized
by CO2 asphyxiation. Brains were removed and longitu-
dinally cut into hemispheric sections and immediately
frozen in sample tubes placed on dry ice. The tissue was
stored frozen at −80°C until processing.
Tissue processing and quantitative real-time RT-PCR
(qRT-PCR) analysis
Expression of cytokines and genes associated with im-
mune activation was measured in brain to determine if
ICE KO mice had differential pro- or anti-inflammatory
responses to LPS compared to WT mice. One hemisphere
of each brain was removed from storage and 3 mL of cold
Trizol reagent (Invitrogen, Carlsbad, CA, USA) were
added to each sample. The tissue was then homogenized
using an ultrasonic tissue disruptor (Sonics and Materials
Inc., Newborn, CT, USA). An E.Z.N.A kit was used to iso-
late total RNA (Omega Bio-tek, Norcross, GA, USA).
RNA purity (OD 260/280) and quantity was assessed
using a Nanodrop Spectrophotometer (Nanodrop Prod-
ucts, Wilmington, DE, USA) and submitted to reverse
transcription using a High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems, Foster City, CA, USA).
The cDNA samples were analyzed using qRT-PCR with
the Prism 7900HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). TaqMan gene expres-
sion assays (Applied Biosystems, Foster City, CA, USA) or
PrimeTime qPCR assays (Integrated DNA Technologies,
Coralville, IA, USA) were used for the detection of IL-1β
/pro-IL-1β (catalog no. Mm00434228_m1), IL-1RA
(Mm00446186_m1), ICE (Mm.PT.49a.21858521), IL-18
(Mm00434225_m1), TNF-α (Mm00443260_g1), IL-6
(Mm00446190_m1), IL-10 (Mm00439614_m1), CD11b
(Mm00434455_m1), MHC II (Mm00439226_m1), GFAP
(Mm00546086_m1), and GAPDH (Mm99999915_g1). All
assays except for ICE and IL-1R1 were purchased from
Applied Biosystems. Samples were analyzed in duplicate
using 125 ng of cDNA template mixed with Taqman Uni-
versal Master Mix and target primers for each reaction
according to the manufacturer’s instructions. Relative
quantitative measurement of target gene levels was per-
formed using the ΔΔCt method, where Ct is the compara-
tive threshold concentration. GAPDH was used as the
endogenous housekeeping control gene to which all other
genes were compared.
Statistical analysis
Data are represented as the means ± SEM. All measures
were analyzed using two-way analysis of variance
(ANOVA). When the two-way interaction P value was
<0.05, post-hoc analysis using Fisher’s protected least
significant difference test was employed to test for diffe-
rences among means.
Results
Sickness responses were similar in WT and ICE KO mice
following central LPS injection
LPS administered ICV decreased body weight of both
WT and ICE KO mice (Table 1) over the 24-h period
following treatment. Only the main effect of LPS was
statistically significant (LPS main effect, F1,24 = 45.50,
P <0.01). Locomotor activity was tested 24 h following
treatment (Table 1). LPS, given ICV, did not affect line
crossings (LPS main effect, F1,26 = 0.28, P >0.05) and
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rearings (LPS main effect, F1,26 = 0.002, P >0.05) of either
strain 24 h after treatment. However, ICE KO mice
displayed reduced line crossings (strain main effect, F1,26 =
27.50, P <0.01) and rearings (strain main effect, F1,26 =
21.62, P <0.01) compared to WT mice. Despite the base-
line difference in activity between the two strains, these
responses indicate that deletion of ICE does not change
the sickness response when LPS is administered centrally.
ICE KO mice were protected from central LPS-induced
depression-like behavior
To test the hypothesis that ICE KO mice would be
protected from central LPS-induced depression-like be-
havior, we employed the FST and sucrose preference test
following ICV treatment with LPS or saline. Importantly
and in agreement with our hypothesis, LPS increased
(strain x LPS interaction; F3,24 = 4.35, P <0.05) immobi-
lity during the FST (Figure 1a) of WT but not ICE KO
mice. Similarly, ICE KO but not WT mice maintained
(strain x LPS interaction; F3,40 = 6.56, P <0.05) their
preference for a 1% sucrose solution over water follow-
ing LPS treatment (Figure 1b). Taken together, these
data confirm that ICE is necessary for expression of
depression-like behavior following central administration
of LPS.
Steady-state expression of brain inflammatory markers
declined faster in ICE KO compared to WT mice
To identify underlying substrates in ICE KO mice that are
related to them being protected from ICV LPS-induced
depression-like behavior, we utilized qRT-PCR to measure
expression of cytokines and markers of active glia in brain
collected 4 and 24 h after treatment. As expected, LPS in-
duced (P <0.01; data not shown) expression of ICE in WT
mice at both time points although central LPS did not
change IL-18 expression (data not shown).
To determine whether ICE deletion reduces neuroin-
flammation, we examined brain expression of pro-
inflammatory cytokines (Figure 2a). LPS increased (LPS
main effect; F1,22 = 91.63, P <0.01) IL-1β expression in
both WT and ICE KO mice at 4 h indicating that LPS
induces a similar initial inflammatory response in both
strains. However, at 24 h, expression of IL-1β remained
elevated (strain x LPS interaction; F3,20 = 10.09, P <0.01)
only in WT mice. LPS-treated ICE KO and WT mice
had increased (LPS main effect; F1,22 = 4.36, P <0.01)
Table 1 Sickness response measures following ICV LPS
Δ Body weight
(g / 24 h)
Line crossings
(# / 5 min)
Rearings
(# / 5 min)
WT −0.10 ± 0.12a 62.7 ± 5.5a 50.3 ± 5.0a
WT-LPS −1.83 ± 0.39b 63.3 ± 6.5a 47.9 ± 5.0a
ICE KO 0.17 ± 0.13a 30.0 ± 2.6b 25.7 ± 1.9b
ICE KO-LPS −1.64 ± 0.12b 35.5 ± 6.4b 28.5 ± 5.2b
Body weight was measured at 0 and 24 h and body weight change was
calculated from these measures; locomotor activity was tested 24 h after
treatment. Averages within columns with different superscript letters are
significantly different; P <0.05.
Figure 1 ICE KO mice were protected from depression-like
behaviors following ICV administration of LPS compared to WT
mice. (a) Time of immobility in the FST was determined 24 h after
treatment. WT mice given LPS had greater time spent immobile
compared to control WT mice, while immobility time in LPS-treated
ICE KO mice was not different from control mice. (b) WT, but not ICE
KO, mice displayed decreased preference for sucrose during the 24
to 48 h period following LPS injection. Data represent averages ±
SEM. n = 9 to 12 mice per group, *P <0.05 comparing bracketed
treatment groups.
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brain expression of TNF-α mRNA at 4 h compared to
controls, but TNF-α expression returned (strain x LPS
interaction; F3,20 = 5.72, P <0.05) to control levels in ICE
KO mice by 24 h after treatment while TNF-α expres-
sion remained elevated in WT mice. At 4 h after
treatment, LPS induced IL-6 expression (strain × LPS
interaction; F3,20 = 10.19, P <0.05) but the LPS response
was smaller in ICE KO mice compared to LPS-treated
WT mice. At 24 h, brain IL-6 expression was increased
by LPS (LPS main effect; F1,22 = 5.52, P <0.05). However,
Figure 2 Expression of pro-inflammatory cytokines in brain was reduced in ICE KO mice at 24 h following LPS given ICV. (a) LPS
increased mRNA expression of IL-1β, TNF-α, and IL-6 in WT and ICE KO at 4 h. Expression of IL-1β and TNF-α remained elevated in brains of only WT
mice at 24 h. (b) IL-10 expression was increased similarly by central LPS in both strains of mice at 4 h and 24 h. In contrast, IL-1RA mRNA expression
increased in both strains at 4 h but remained elevated at 24 h only in WT mice. (c) CD11b and GFAP expression were increased similarly in WT and ICE
KO brains at 4 h. At 24 h, CD11b expression was reduced in ICE KO mice compared to WT mouse brains following ICV administration of LPS. Data are
average mRNA expression levels relative to GAPDH ± SEM; **P <0.01, *P <0.05 comparing bracketed groups; main effects of LPS where indicated;
n = 6 mice per group. Insets: Data presented with zoomed in scale to ease interpretation. Mean Ct values for saline treated WT groups were: IL-1β,
31.7 ± 0.4; TNF-α, 32.0 ± 0.3; IL-6, 31.6 ± 0.4; IL-10, 34.6 ± 0.2; IL-1RA, 33.2 ± 0.3; CD11b, 20.7 ± 0.03; GFAP, 17.4 ± 0.1.
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ICE KO mice tended (strain x LPS interaction; F3,20 =
3.84, P = 0.06) to have reduced brain IL-6 expression
24 h after ICV injection of LPS.
We examined expression of IL-10 and IL-1RA within
the brain to determine if ICE deletion leads to increased
expression of anti-inflammatory genes (Figure 2b). IL-10
mRNA increased similarly in both strains at 4 (LPS main
effect; F1,22 = 22.38, P <0.01) and 24 h (LPS main effect;
F1,22 = 16.00, P <0.01) after treatment. IL-1RA, which is an
IL-1β-signaling antagonist, was increased (LPS main effect;
F1,22 = 66.24, P <0.01) in both strains in response to central
LPS. However, in agreement with IL-1β data, IL-1RA
remained elevated (strain x LPS interaction; F3,20 = 13.10,
P <0.01) only in LPS-treated WT mice at 24 h.
Consistent with reductions in pro-inflammatory cyto-
kine expression, the expression of genes associated with
glial activation was diminished in LPS-treated ICE KO
mice compared to LPS-treated WT mice (Figure 2c).
CD11b expression was not influenced by LPS 4 h after
treatment but was significantly lower (strain x LPS inter-
action; F3,20 = 8.55, P <0.01) in LPS-treated ICE KO
mice compared to LPS-treated WT mice at 24 h. LPS in-
creased (LPS main effect; F1,22 = 24.65, P <0.01) expression
of the astrocyte activation marker GFAP at 4 h post treat-
ment in both strains of mice. ICE KO mice tended to have
lower expression (strain x LPS interaction; F1,22 = 3.87,
P = 0.06) of GFAP at 24 h.
The similar expression of cytokines in the brains of
ICE KO and WT mice at 4 h agrees with their similar
sickness response. The reduced cytokine expression in
the brains of ICE KO mice compared to WT mice, at
24 h, coincides with the lack of depression-like behaviors
following ICV LPS of ICE KO mice, indicating that cen-
tral cytokines are involved in depression-like behaviors
associated with neuroinflammation.
Systemic LPS administration induced a similar sickness
response in ICE KO and WT mice
To determine if sickness responses are similar in ICE
KO and WT mice following peripheral administration of
LPS, body weight was recorded immediately prior to and
24 h after treatment in both strains of mice (Table 2).
Change in body weight was calculated and used as one
index of sickness following systemic LPS challenge. Both
ICE KO and WT mice treated with LPS displayed re-
duced (LPS main effect; F1,45 = 692.01, P <0.01) body
weight at 24 h post treatment. ICE KO and WT mice
had similar sickness response following IP LPS chal-
lenge, indicating that ICE deletion does not prevent sick-
ness response to systemic LPS. Locomotor activity was
also tested in all mice 24 h post-treatment (Table 2).
WT but not ICE KO mice treated with LPS had a re-
duced (strain x LPS interaction; F3,43 = 10.56, P <0.01)
number of line crossings and rearing in this locomotor
activity test compared to saline treated controls. As ob-
served in the central LPS studies, ICE KO mice, regard-
less of treatment, had fewer line crossing and rearings
compared to saline-treated WT mice (P <0.01). ICE KO
mice appear to be recovered from reductions in loco-
motor activity following systemic LPS, although their
loss of body weight is similar.
Peripheral LPS increased FST immobility and decreased
sucrose preference of both WT and ICE KO mice
To test the hypothesis that ICE KO mice would not be
protected from systemic LPS-induced depression-like
behavior, we submitted both strains of mice to FST and
sucrose preference test following IP administration of
LPS or saline. During the FST, LPS increased (LPS
main effect; F1,45 = 10.33, P <0.01) time of immobility
similarly of both WT and ICE KO mice (Figure 3a).
To determine whether ICE KO mice developed an
anhedonic response, preference for a 1% sucrose solu-
tion from 24 to 48 h post treatment was quantified
(Figure 3b). Both WT and ICE KO mice treated IP
with LPS had reduced (LPS main effect; F1,22 = 4.76,
P <0.05) sucrose preference. These data confirm our
hypothesis that deletion of ICE does not protect
against depression-like behavior following systemic ad-
ministration of LPS.
A peripheral LPS challenge increased expression of pro-
inflammatory cytokines and glial activation markers
similarly in the brains of both WT and ICE KO mice
To evaluate whether LPS increased steady-state expres-
sion of mRNA for inflammatory mediators similarly in
WT and ICE KO mice, qRT-PCR was used to quantify
mRNA expression in brain after IP treatment with LPS
or saline. Consistent with data from the central LPS
studies, ICE expression was increased (P <0.05) at 4 and
24 h by LPS in WT mice only. Interestingly, systemic
LPS increased (LPS main effect; F1,21 = 5.53, P <0.05)
brain IL-18 expression in both strains at 4 h but not at
24 h (P >0.1; data not shown). Systemic LPS (Figure 4a)
similarly increased (LPS main effect; F1,21 = 127.96,
Table 2 Sickness response measures following IP LPS
Δ Body weight
(g / 24 h)
Line crossings
(# / 5 min)
Rearings
(# / 5 min)
WT −0.02 ± 0.11a 60.3 ± 5.6a 42.9 ± 5.0a
WT-LPS −2.84 ± 0.09b 36.8 ± 6.5b 26.9 ± 3.0b
ICE KO −0.09 ± 0.10a 35.6 ± 3.8b 27.0 ± 3.0b
ICE KO-LPS −2.82 ± 0.12b 36.9 ± 2.6b 25.2 ± 2.4b
Body weight was measured at 0 and 24 h and body weight change was
calculated from these measures; locomotor activity was tested 24 h after
treatment. Averages within columns with different superscript letters are
significantly different; P <0.05.
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P <0.01) brain expression of IL-1β in both WT and ICE
KO mice at 4 h after treatment. However at 24 h, ICE
KO mice had lower (strain x LPS interaction; F3,19 =
6.58, P <0.05) IL-1β expression relative to LPS-treated
WT mice 24 h after treatment. In contrast to central
LPS-treated ICE KO mice, IL-1β remained elevated in
systemic LPS-treated ICE KO mice relative to controls.
Systemic LPS increased brain TNF-α (LPS main effect;
F1,21 = 192.89, P <0.01) and IL-6 (LPS main effect; F1,21
= 41.72, P <0.01) expression at 4 h. TNF-α expression
remained elevated (LPS F1,21 = 121.70, P <0.01) at 24 h,
while IL-6 was reduced (LPS main effect; F1,21 = 5.68,
P <0.05) in both strains of mice. Importantly, there were
no strain differences in TNF-α or IL-6 expression.
Brain expression of IL-10 and IL-1RA was measured to
determine whether these transcripts were similar in ICE
KO and WT mice treated with systemic LPS (Figure 4b).
Four hours following an IP injection of LPS, IL-10 (strain
x LPS interaction; F3,19 = 6.83, P <0.05) and IL-1RA (strain
x LPS interaction; F3,19 = 6.83, P <0.05) expression were
greater in ICE KO mice compared to LPS-treated WT
mice. By 24 h, both strains had similar increases (LPS
main effect; F1,21 = 68.83, P <0.01) in brain IL-10. How-
ever, LPS-induced IL-1RA expression was lower (strain ×
LPS interaction; F3,19 = 7.34, P <0.05) in ICE KO than WT
mice at 24 h after treatment but still remained elevated
compared to control mice.
To determine if ICE influenced activation of glia in re-
sponse to systemic LPS, we measured expression of micro-
glia and astrocyte activation markers in brain (Figure 4c).
LPS induced CD11b (LPS main effect; F1,21 = 200.97,
P <0.01) expression similarly in both ICE KO and WT
mice at 24 h only. Brain GFAP expression was increased
similarly at 4 h (LPS main effect; F1,21 = 9.06, P <0.01) and
24 h (LPS main effect; F1,21 = 96.48, P <0.01)in both strains
following peripheral LPS treatment. These data indicate
that glial activation is similar in both ICE KO and WT fol-
lowing systemic LPS, unlike what was observed in ICE KO
mice following central injection of LPS.
With the exception of IL-1β and IL-1RA expression,
both ICE KO and WT mice have similar expression of
genes in the brain that are associated with inflammation
following systemic LPS. These gene expression data
agree well with the induction of a similar depression-like
behavior in both strains following systemic LPS.
Discussion
We previously demonstrated that ICE KO mice are resist-
ant to central LPS-induced reduction in food intake [24]
and feeding behavior [23]. However, ICE KO mice lack this
protection following systemic LPS administration [23] al-
though they are protected against peripheral endotoxic
shock induced by higher doses of LPS [33]. These findings
suggested that there is a distinction between responses elic-
ited by an activation of the central innate immune system
versus the peripheral immune system. Given the more re-
cent data showing that IL-1 is critically involved in the de-
velopment of depression-like behaviors [10,16,34,35], these
findings stimulated us to test the hypothesis that ICE KO
mice might be protected from central but not peripheral
LPS-induced depression-like behaviors. To our knowledge,
Figure 3 Both ICE KO and WT mice displayed depression-like
behaviors following IP LPS challenge. LPS given systemically
increased (a) immobility in the FST 24 h after treatment and decreased
(b) sucrose preference when measured 24 to 48 h post-treatment
similarly in both mouse strains. Data represent averages ± SEM; main
effects of LPS where indicated; n = 6 mice per group.
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we are now the first to report that ICE is required for de-
velopment of depression-like behavior following a central,
but not systemic, LPS challenge.
ICE is a cysteine protease and is the enzyme principally
responsible for cleavage of two critical pro-inflammatory
cytokines, pro-IL-1β and pro-IL18, from their inactive pre-
cursors to their mature active secreted forms. ICE is con-
stitutively present within cells as an inactive precursor co-
localizing with a group of proteins that collectively form
the inflammasome. Inflammasomes contain nucleotide
Figure 4 Both ICE KO and WT mice given systemic LPS exhibited increased expression of inflammatory markers in brain. In both WT and
ICE KO mice, LPS injected IP induced expression of (a) IL-1β, TNF-α, and IL-6 at 4 h. All but IL-6 remained elevated at 24 h. (b) ICE KO mice had greater
expression of IL-10 and IL-1RA at 4 h. However, at 24 h, the LPS-induced increase in IL-10 expression was similar in both strains of mice while that of IL-1RA
was reduced in ICE KO mice. (c) CD11b was not elevated by LPS until 24 h post-treatment while GFAP expression was increased at both 4 h and 24 h
similarly in WT and ICE KO mice. Data are average mRNA expression levels relative to GAPDH ± SEM, **P <0.01, *P <0.05 comparing bracketed groups; main
effects of LPS where indicated; n = 5 to 6 mice per group. Insets: Data presented with zoomed in scale to ease interpretation. Mean Ct values for saline
treated WT groups were: IL-1β, 29.5 ± 0.1; TNF-α, 29.6 ± 0.1; IL-6, 29.2 ± 0.1; IL-10, 34.9 ±0.1; IL-1RA, 30.4 ± 0.3; CD11b, 21.6 ± 0.1; GFAP, 18.0 ± 0.1.
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and oligomerization domain-like receptor (NLR) family
proteins that act as intracellular receptors for pathogen-
associated molecular patterns (PAMPs) or danger-
associated molecular patterns (DAMPs) in a similar fash-
ion as the widely recognized toll-like receptors [22,36,37].
Following recognition of PAMPs and DAMPs by NLRs,
there is a transient increase in ICE activity [20]. The pre-
cise mechanism by which LPS can directly activate
inflammasomes and ICE activity has not been fully eluci-
dated. However, LPS-induced upregulation of ICE expres-
sion has largely been shown to occur in cells of the
myeloid lineage such as central microglia [18] and periph-
eral monocytes/macrophages [19]. We confirmed that ICE
expression in the brain was upregulated by both central
and peripheral LPS in WT mice.
ICE activity has substantial influence over behavioral
responses during inflammation, presumably through its
role in processing inactive IL-1β [20]. Genetic deletion
of ICE decreases LPS-induced IL-1β secretion [33].
It has been well established that IL-1β activates the
hypothalamic-pituitary-adrenal axis and induces behav-
ioral changes associated with sickness and depression,
such as anhedonia, disruption of sleep, cognitive distur-
bances, temperature disregulation, and consumption of
food [9,26,27]. Our findings indicate a prominent role
for central ICE during inflammation-induced depression.
These new data are in in agreement with recent work
that has demonstrated a role for IL-1ß in the develop-
ment of depression-like behavior utilizing a variety of
models. Chronic exposure to IL-1β diminished sucrose
preference and social exploration; which are indicative
of the depressive symptoms of anhedonia and social
withdrawal, respectively [10,28]. Chronic mild stress
(CMS) of mice not only elevates IL-1β levels but also
results in depression-like symptoms, including a de-
crease in sucrose preference (to the point of aversion)
and decreased social exploration. These symptoms are
dependent on IL-1β as either type 1 IL-1 receptor
(IL-1R) deficiency or the injection of IL-1 receptor an-
tagonist (IL-1RA) block the effect of CMS [10]. Simi-
larly, several other studies using models of CMS,
chronic unpredictable stress (CUS), chronic pain, and
ischemic stroke have demonstrated that reducing IL-1
signaling blocks depression-like behaviors including re-
duced sucrose preference and increased immobility time
in the FST [16,34,35]. Similar CUS causes mice to dis-
play decreased preference for sucrose solution compared
to unstressed mice, and this anhedonic response is
blocked by ICV administration of IL-1RA [34]. This later
finding is important as it illustrates that IL-1β activity
within the brain is required for the development of
depression-like behavior. Chronic pain has also been
linked to depression with a possible cause and effect re-
lationship [38,39]. Moreover, IL-1 has been extensively
examined for its role in mediating symptoms of neuro-
pathic pain (reviewed in [40]). Utilizing the spared nerve
injury model of chronic pain, increased time of immobil-
ity during the FST was blocked by central administration
of IL-1RA into the lateral ventricle. Middle cerebral ar-
tery occlusion, which is a model of ischemic stroke, leads
to a robust induction of brain IL-1β expression and IL-1
signaling in this model plays an important role in post-
stroke depression as evidenced by a reduction in sucrose
consumption that is blocked when mice are treated with
an ICV injection of IL-1RA [35]. All of these studies
established that brain IL-1 signaling is of significant im-
portance for mediating depression-like behaviors since
each model targeted IL-1 signaling in the brain. All of
these results are in agreement with the new findings
reported here that deletion of ICE blocks the LPS-induced
increase in FST immobility and decrease in sucrose pre-
ference only when LPS is administered centrally. Clearly,
non-ICE dependent mechanisms for depression-like
behavior remain functional when LPS is administered
peripherally.
Despite reduced IL-1β secretion, ICE KO mice have
similar a sickness response compared to WT mice in
terms of loss of body weight following both systemic
and central LPS challenges. This lack of attenuation of
the sickness response is not surprising since IL-1R1
knockout mice also lose body weight similar to WT
mice when treated with ICV or IP LPS [41]. Further,
inhibiting IL-1 signaling with ICV or IP administration
of IL-1RA is not sufficient to block body weight loss in
LPS treated rats [42]. It was postulated several years
ago that LPS-induced sickness behaviors require the
presence of either TNF-α or IL-1β, but when IL-1 sig-
naling is absent, TNF-α assumes a more prominent role
[41]. This postulate is consistent with the present find-
ings that both WT and ICE KO mice displayed elevated
TNF-α expression in the brain following LPS. There-
fore, similar degrees of sickness behavior following LPS
injection in WT and ICE KO mice is consistent with
the known pleiotropic properties of both IL-1β and
TNF-α.
Unexpectedly, ICE KO mice had reduced locomotor
activity as assessed by the number of line crossings and
rearings compared to WT mice. A possible explanation
for reduced exploratory behavior measured in ICE KO
mice is increased anxiety in these mice. Exploratory be-
havior is often used as an important screening tool for
anxiety-like behavior [43]. We cannot rule out the possi-
bility that reduced locomotor activity exhibited by ICE
KO mice is indicative of an anxiogenic phenotype but
our experiments were not designed to properly test this
possibility. However, it is important to note that loco-
motor activity of ICE KO mice 24 h after LPS was un-
affected by either central or systemic LPS challenge. We
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interpret these data to suggest that ICE KO mice display
a more rapid recovery from sickness behavior compared
to WT mice. Again, testing this possibility was not the
focus of our experiments. Importantly for the current
body of work, the decrease in locomotor activity did not
translate into an elevated time of immobility during the
FST. The equal time of immobility of saline-treated WT
and ICE KO mice during this test indicates that reduced
locomotor activity was not due to depression-like behav-
ior and that differences in performance during the FST
did not result from a motor deficit. However, as ICE in-
hibitors may draw increasing interest as treatments for
inflammation-associated diseases, it will be important to
evaluate different alterations for other ICE-dependent
behaviors.
Cytokine signals are propagated diffusely throughout
the brain following an initial immune stimulation. This
propagation occurs primarily by the induction of add-
itional IL-1ß and other pro-inflammatory cytokines in
brain resident cells including microglia [44-48]. Despite
having reduced IL-1β secretion in response to LPS [33],
ICE KO mice still develop depression-like behavior fol-
lowing systemic but not central LPS administration. This
finding alludes to compensatory actions of other periph-
eral cytokines to induce inflammatory mediators within
brain despite the deficiency in mature IL-1β, or a lack of
peripheral IL-1ß involvement in peripherally induced
depression-like behaviors. In our experiments, both WT
and ICE KO mice displayed increased early (4 h) expres-
sion of brain IL-1β, TNF-α and IL-6 following both sys-
temic and central LPS. At 24 h, brain IL-1β and TNF-α
were no longer elevated in central LPS-treated ICE KO
compared to saline-treated ICE KO mice even though
expression of these genes remained elevated in LPS-
treated WT mice. In our model, the reduced induction
of IL-1β mRNA expression following LPS treatment
likely results from a quicker extinguishing of the feed-
forward cytokine signaling, in agreement with data dem-
onstrating that IL-1β induces its own expression and the
expression of TNF-α and IL-6 within brain [49,50]. This
was in contrast to what was observed following systemic
LPS because most inflammatory mediators that we mea-
sured were increased similarly in WT and ICE KO mice.
In contrast, TNF-α expression remained elevated at 24 h
following systemic LPS administration in both WT and
ICE KO mice. This finding indicates that even in the ab-
sence of IL-1ß secretion, TNF-α may mediate depression-
like behavior because its absence in the brain at 24 h in
ICV-treated ICE KO mice corresponds to a lack of
depression-like behavior and its continued presence at 24
h in ICV-LPS WT, IP-LPS WT, and IP-LPS ICE KO mice
corresponds to the presence of depression-like behaviors.
A role for TNF-α in depression-like behavior has been di-
rectly shown. Even extremely low doses of TNF-α
administered ICV causes depression-like behavior as
assessed as increased time of immobility during both the
FST and tail suspension test [51]. In addition, TNF-R1 de-
ficient mice and mice treated with a neutralizing antibody
to TNF-α had a decreased time of immobility during the
FST, indicating an anti-depressant response. This study
supports work showing that TNF receptor deficient mice
have lower immobility during the FST, again indicating an
anti-depressant response. The TNF receptor deficient
mice also have increased consumption of a sucrose solu-
tion, indicative of an anhedonic response mediated by
TNF-α [52]. In further support of a role for TNF-α in de-
pression, human patients afflicted with plaque psoriasis
showed significant improvement in Beck Depression In-
ventory and Hamilton Rating Score for depression when
treated with the TNF neutralizing drug Etanercept [53].
Patients treated with Etanercept showed significant im-
provement in sexual function, sleep, irritability, and other
symptoms of depression that impacted quality of life com-
pared to patients receiving placebo. These data indicate
that TNF-α is probably involved in mediating depression-
like behaviors. Together with our current data, we
hypothesize that in the absence of IL-1ß, depression-like
behavior is present only when central TNF-α expression is
elevated following the LPS challenge.
Expression of IL-10 and IL-1RA in the brain remain ele-
vated in ICE KO and WT mice following systemic LPS ex-
posure at 24 h. This was not the case following central
LPS, further supporting a role for IL-1β in a sustained
brain inflammatory response. Compensatory actions of
other cytokines such as TNF-α [54] contribute to periph-
eral immune activation cascades when IL-1 action is lost.
We also found that ICE KO mice have decreased mRNA
expression of genes associated with microglia and astro-
cyte activation, CD11b and GFAP, following central LPS
treatment. We interpret these findings as evidence that
IL-1β is important for maintaining activation of glial cells
in response to neuroinflammation. Indeed, reduced cy-
tokine expression observed in ICE KO following central
LPS is reflective of reduced glial cell activation. We are
intrigued by our finding that brain MHCII expression
was not different between ICE KO and WT mice fol-
lowing central LPS (data not shown) as this may in-
dicate a less prominent role for IL-1β to induce an
antigen presenting phenotype in microglia. Based on
these data, our results add to evidence that ICE and
subsequently IL-1ß signaling plays a necessary role for
initiating and sustaining a full inflammatory response
within the brain that manifests behaviors associated
with depression.
Conclusions
To our knowledge, we are first to report that ICE KO
mice are protected from central LPS-induced depression-
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like behavior. Deletion of ICE has a significant impact
on the inflammatory profile in brain following ICV LPS
but essentially no effect on the brain following a periph-
eral LPS challenge. We propose that targeting of ICE
represents a potential therapeutic target directed at
treating neuroinflammation-dependent comorbid de-
pression.
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